Literature DB >> 18033831

Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit.

Naoyuki Miyashita1, Yasushi Obase1, Kazunobu Ouchi2, Kozo Kawasaki2, Yasuhiro Kawai2, Yoshihiro Kobashi1, Mikio Oka1.   

Abstract

Community-acquired pneumonia (CAP) due to Mycoplasma pneumoniae is usually mild, but some cases develop a severe life-threatening pneumonia. To investigate the clinical features of severe M. pneumoniae pneumonia in adults admitted to an intensive care unit, a multi-centre CAP surveillance study was performed. Among all hospitalized CAP cases between January 2000 and December 2004, there were 227 cases with M. pneumoniae pneumonia without the complication of other pathogens. A total of 13 of the cases required admission to an intensive care unit because of acute respiratory failure (ARF), and the remaining 214 cases (non-ARF) were low to moderately severe. The clinical features of ARF cases were compared with those of non-ARF cases. The underlying conditions in both types of case were identical, whereas clinical findings on admission clearly differed between the two groups. A regimen of an antibiotic effective against M. pneumoniae was begun on average at 9.3 days after the onset of symptoms in ARF cases, which was significantly later than for non-ARF cases (P<0.0001). However, two of the ARF cases progressed to respiratory failure despite the fact that adequate antibiotics were initially administered within 3 days after the onset of symptoms. All ARF cases received corticosteroids with adequate antibiotics, and their condition improved promptly. These results indicate that the clinical features, excluding underlying conditions, clearly differed between severe M. pneumoniae pneumonia and low to moderately severe pneumonia. The delayed administration of adequate antibiotics may contribute to the severity of M. pneumoniae pneumonia. Early corticosteroid therapy with adequate antibiotics should be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18033831     DOI: 10.1099/jmm.0.47119-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  42 in total

1.  Acute respiratory distress syndrome caused by Mycoplasma pneumoniae without elevated pulmonary vascular permeability: a case report.

Authors:  Naoki Takahashi; Tsutomu Shinohara; Rie Oi; Muneyuki Ota; Shinichi Toriumi; Fumitaka Ogushi
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

2.  Clinical severity of Mycoplasma pneumoniae (MP) infection is associated with bacterial load in oropharyngeal secretions but not with MP genotype.

Authors:  Anna C Nilsson; Per Björkman; Christina Welinder-Olsson; Anders Widell; Kenneth Persson
Journal:  BMC Infect Dis       Date:  2010-02-25       Impact factor: 3.090

Review 3.  Community-acquired pneumonia related to intracellular pathogens.

Authors:  Catia Cillóniz; Antoni Torres; Michael Niederman; Menno van der Eerden; James Chalmers; Tobias Welte; Francesco Blasi
Journal:  Intensive Care Med       Date:  2016-06-08       Impact factor: 17.440

4.  Ciliary ultrastructural abnormalities in Mycoplasma pneumoniae pneumonia in 22 pediatric patients.

Authors:  Hui Liang; Wujun Jiang; Qing Han; Feng Liu; Deyu Zhao
Journal:  Eur J Pediatr       Date:  2011-10-26       Impact factor: 3.183

5.  Clinical potential of diagnostic methods for the rapid diagnosis of Mycoplasma pneumoniae pneumonia in adults.

Authors:  N Miyashita; Y Kawai; T Yamaguchi; K Ouchi; M Oka
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-03       Impact factor: 3.267

6.  Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia.

Authors:  You-Sook Youn; Kyung-Yil Lee; Ja-Young Hwang; Jung-Woo Rhim; Jin-Han Kang; Joon-Sung Lee; Ji-Chang Kim
Journal:  BMC Pediatr       Date:  2010-07-06       Impact factor: 2.125

7.  Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.

Authors:  David Oldach; Kay Clark; Jennifer Schranz; Anita Das; J Carl Craft; Drusilla Scott; Brian D Jamieson; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

8.  The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection.

Authors:  C Tagliabue; C M Salvatore; C Techasaensiri; A Mejias; J P Torres; K Katz; A M Gomez; S Esposito; N Principi; R D Hardy
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

9.  Baicalin relieves Mycoplasma pneumoniae infection‑induced lung injury through regulating microRNA‑221 to inhibit the TLR4/NF‑κB signaling pathway.

Authors:  Han Zhang; Xiang Li; Juan Wang; Qi Cheng; Yunxiao Shang; Guizhen Wang
Journal:  Mol Med Rep       Date:  2021-06-10       Impact factor: 2.952

10.  Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing.

Authors:  Naoyuki Miyashita; Tadaaki Sugiu; Yasuhiro Kawai; Keiko Oda; Tetsuya Yamaguchi; Kazunobu Ouchi; Yoshihiro Kobashi; Mikio Oka
Journal:  BMC Med Imaging       Date:  2009-04-29       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.